【摘要】 目的本研究旨在观察在中国初治急性髓系白血病(AML)患者中采用标准剂量伊达比星(12 mg/m2×3 d)联合阿糖胞苷方案诱导的远近期疗效和毒副作用。方法总结了2005年5月1日至2012年4月1日在我院接受标准剂量诱导治疗的AML患者36例,按照WHO化疗方案急性及亚急性毒性分级标准进行分级和记录,分析近期疗效及远期预后。结果在36例患者中26例(72.2%)患者达到完全缓解(CR);5例(13.9%)为部分缓解(PR),总体缓解率(ORR)为86.1%;主要3~4级毒副作用为血液学毒性(97.2%)、感染(19.5%)、胃肠道反应(8.3%);2年总体生存率(OS)为76.4%,2年无进展生存率(PFS)为58.5%。结论在我国初治AML患者中使用标准剂量IDA/AraC的诱导方案能够取得较满意的近期疗效和远期预后,其毒性反应可耐受,为后续治疗创造了机会。更多还原

【Abstract】 Objective To evaluate the treatment effects and adverse effects of standard dose idarubicin combined with cytarabine induction regimen in Chinese newly-diagnostic acute myeloid leukemia(AML) patients. Methods We retrospectively analyzed 36 AML patients treated in our center between August 1st 2005 to December 31st 2010, who received at least one cycle of standard dose idarubicin induction regimen. The acute and sub-acute adverse effects were recorded according WHO criteria. Response rate and long-term outcome were calculated. Results Among the 36 evaluable patients 26(72.2%) achieved a complete response(CR), while another 5 patients(13.9%) a partial response(PR). The overall response rate was 86.1%. Major Grade 3-4 adverse effects(AE) were hematological AEs(97.2%), infections(19.5%) and gastrointestinal AEs(8.3%). 2 years overall survival rate was 76.4%, and 2 years progression-free survival rate was 58.5%. Conclusion Standard dose IA regimen as induction for newly-diagnostic Chinese AML patients was effective and well-tolerated.更多还原